RAIsonance, Inc., a group of Artificial Intelligence – Machine Learning (AI-ML) technology solutions companies, today announced the promotion of Paul McLenaghan to Chief Revenue Officer and the hiring of Kris Hopkins as Chief Product Officer.
Paul McLenaghan, Chief Revenue Officer
Paul McLenaghan joined RAIsonance in July 2021 as SVP of Market Development. He is a market and business development executive with a passion for driving market disruption. Since joining RAIsonance, he has worked with executive leadership to develop strategic relationships, identify new market opportunities, and drive go to market activities across the government, private enterprise, and education sectors.
Prior to RAIsonance, Paul spent close to twenty years in the advertising technology industry. He was most recently with Prohaska Consulting, where he consulted to major ad tech platforms, publishers, and media companies on data strategy and new product strategy. Previously, he spent close to fifteen years at TARGUSinfo and Neustar, where he had a track record of success creating and driving new solutions and lines of business at the intersection of technology, data, and media in executive roles across Product Strategy and Market Development.
Paul completed his MBA at the University of Maryland Robert H. Smith School of Business and has BA degrees in Economics and English from Villanova University. He is a dual citizen of Australia and the United States.
Kris Hopkins, Chief Product Officer
Kris Hopkins is an entrepreneur, inventor, and product leader in software. Previously, Kris has led strategy, product, and engineering as CTO and/or Chief Product Officer at multiple companies including at Perfecta, a cybersecurity, intelligence, and communications technology provider, and led strategic product management for new products at Oracle. As founder and CEO of Newfound Communications, Kris sold the company to Acme Packet (NASDAQ: APKT) and spun out its Software as a Service business into Surgent Networks. A dynamic leader of software product and development teams, Kris brings to RAIsonance 20 years of experience managing mission-critical and high-security software development projects and pipelines. With a focus on the largest enterprise and government customers, his leadership builds robust cloud-based and premise-based software products, SDKs, and APIs for businesses to provide secure and efficient solutions.
Kris is a graduate of Cornell University where he was the recipient of the Dorman Family Award for Entrepreneurship and Personal Enterprise Excellence. He is a dedicated husband, father of two, loves coaching youth sports, and is an active member of his community.
Driving a Revolution in AI-ML Technology for Healthcare
Mr. Hopkins and Mr. McLenaghan join RAIsonance’s executive team at a critical moment in the company’s growth. Founded in March of 2020, the company set out to devise and bring to market the first software only, AI-powered COVID test using only the sound of a person’s cough to render a diagnosis. The device, called AudibleHealth Dx, is designed to diagnose COVID-19 by analyzing the sound of a person’s forced cough vocalization using artificial intelligence.
The user interface takes the form of a mobile app. Once the user downloads and registers on the app, they cough 4 to 6 times into their mobile phone, and in about 2 minutes after submitting a cough, they receive their test result in the app. This all-digital approach allows for fast and easy COVID-19 testing with no swabs, no lines, no waste, no expiration dates, and no waiting. The massively scalable testing platform is capable of processing many thousands of tests per second and is integrated with the company’s TestHub digital test acquisition, distribution, and tracking platform.
The RAIsonance team successfully completed its EUA clinical trials for the COVID test in late 2022 and has filed applications for Emergency Use Authorization in the US and Canada. The company is currently working on its second and third tests on the platform, for Influenza and Tuberculosis.
Of the new hires, RAIsonance Co-Founder and CEO, Kitty Kolding, said, “Kris and Paul are both impressive, accomplished executives. They join our executive team at the perfect moment as we launch several new AI-ML health tech solutions while continuing development on our Software as a Medical Device (SaMD).”
When asked about his role at RAIsonance, Kris Hopkins replied, “Since the onset of the global pandemic, AI and Machine Learning have held great promise for the diagnosis and wellness assessments of respiratory ailments. As Chief Product Officer, I am looking forward to building upon and extending the impressive work by the RAIsonance team. We are in a position to deliver secure, breakthrough products which leverage our experience with AI/ML bio-acoustic markers for the reliable detection of respiratory conditions, leading to improved outcomes and better health equity.”
Paul McLenaghan said about his promotion to Chief Revenue Officer, “I joined RAIsonance in 2021 to contribute to the company’s mission to have a positive impact on global health and wellness. It has been a privilege to work alongside such a talented and passionate team these past 18 months to develop a suite of innovative, 100% digital diagnostic and wellness solutions that are affordable, reliable, and scalable. I look forward to working with Kitty and the rest of the team to deliver our solutions to health providers, public health officials, employers, and most importantly - individuals in the US and globally.”
About RAIsonance, Inc.
RAIsonance, Inc., a family of AI-powered technology solution companies headquartered in the Denver Tech Center, is focused on meeting today’s critical health and safety challenges. Founded in March of 2020, AudibleHealth AI, Inc. is the SaMD division of RAIsonance, specializing in AI/ML diagnostic solutions and platforms. Originally funded by an SBIR grant by the National Science Foundation, the team of medical, artificial intelligence, technology, and medical device specialists focuses on developing leading-edge AI/ML-based, scalable, cost-effective diagnostic products across a range of acute and chronic health conditions.